Search results
Results From The WOW.Com Content Network
The International Classification of Diseases for Oncology (ICD-O) is a domain-specific extension of the International Statistical Classification of Diseases and Related Health Problems for tumor diseases. This classification is widely used by cancer registries. It is currently in its third revision (ICD-O-3). ICD-10 includes a list of ...
Hematological malignancies are malignant neoplasms ("cancer"), and they are generally treated by specialists in hematology and/or oncology. In some centers "hematology/oncology" is a single subspecialty of internal medicine while in others they are considered separate divisions (there are also surgical and radiation oncologists).
ICD-10 is the 10th revision of the International Classification of Diseases (ICD), a medical classification list by the World Health Organization (WHO). It contains codes for diseases, signs and symptoms, abnormal findings, complaints, social circumstances, and external causes of injury or diseases. [1]
192 Malignant neoplasm of other and unspecified parts of nervous system. 192.0 Cranial nerve; 192.1 Cerebral meninges. Meningioma; 192.2 Spinal cord; 192.3 Spinal meninges; 193 Malignant neoplasm of thyroid gland; 194 Malignant neoplasm of other endocrine glands and related structures; 195 Malignant neoplasm of other and ill-defined sites
Malignant rhabdoid tumour (MRT) is a very aggressive form of tumour originally described as a variant of Wilms' tumour, which is primarily a kidney tumour that occurs mainly in children. MRT was first described as a variant of Wilms' tumour of the kidney in 1978. [1] MRTs are a rare and highly malignant childhood neoplasm.
Carcinoma is a malignancy that develops from epithelial cells. [1] Specifically, a carcinoma is a cancer that begins in a tissue that lines the inner or outer surfaces of the body, and that arises from cells originating in the endodermal, mesodermal [2] or ectodermal germ layer during embryogenesis.
The concept of grading of the tumors of the central nervous system, agreeing for such the regulation of the "progressiveness" of these neoplasias (from benign and localized tumors to malignant and infiltrating tumors), dates back to 1926 and was introduced by P. Bailey and H. Cushing, [1] in the elaboration of what turned out the first systematic classification of gliomas.
When molecular diagnostics are not complete enough to allow precise classification, diagnosis should be designated by appending not otherwise specified (NOS). In case of a full molecular workup which does not match any of the standard WHO diagnosis, tumors are to be labeled not elsewhere classified (NEC). [3]